BRIEF-Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN
April 14 (Reuters) - Oncolytics Biotech Inc
* Analysis showed a statistically significantly higher percentage of patients surviving two years in test arm versus control arm
* Says at time of data cut off, there were five survivors on study in test arm, and one survivor on study in crossover arm
* Two- and three-year survival for arms may continue to evolve Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.